|Mr. John Chongbo Rim||CEO, Pres & Director||1.09B||N/A||1961|
|Mr. James J. Choi||Chief Information Officer and VP||569M||N/A||1967|
|Dr. Kyusung Lee||Exec. VP of Gen. Manufacturing Technology||993M||N/A||1960|
|Yoon Kwanghun||Exec. VP||1.03B||N/A||N/A|
|Mr. Dong-Joong Kim||CFO, Sr. VP, MD & Director||N/A||N/A||1965|
|Hyung Woo Moon||Compliance Officer||N/A||N/A||N/A|
|Mr. Andy Yongsin Kim||CHRO & VP||N/A||N/A||1964|
|Mr. Hoyeol Yoon||Sr. VP||N/A||N/A||1963|
|Mr. James Park||Sr. VP, MD & CBO||N/A||N/A||1966|
|Mr. Gwanghun Yun||Exec. VP of Gen. plant, Construction & Infrastructure||N/A||N/A||1956|
Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. It is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company has a strategic partnership agreement with Kineta, Inc. Samsung Biologics Co., Ltd. was founded in 2011 and is headquartered in Incheon, South Korea.
Samsung Biologics Co.,Ltd.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 10; Compensation: 8.